Geoffrey von Maltzahn
General Partner
Geoffrey von Maltzahn joined 蘑菇视频APP in 2009 and serves as general partner. He is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies that integrate biology and data science to transform human health and sustainability.
Geoffrey has co-founded companies that have, in aggregate, achieved over $10 billion in public and private market capitalization. Through his role in Flagship Labs, the company鈥檚 innovation foundry, Geoffrey has created companies that include Lila Sciences, , Mirai Bio, Tessera Therapeutics, Generate:Biomedicines, , Sana Biotechnology (NASDAQ: SANA), and Seres Therapeutics (NASDAQ: MCRB). These are pioneering, respectively, scientific superintelligence, somatic genomics, fully integrated end-to-end genetic medicines development, Gene Writing鈩�, generative biology, carbon farming and plant microbiome products, engineered cells and cell-specific gene therapies, and the first human microbiome therapeutics.
Geoffrey currently serves as CEO and board member of Lila Sciences, board chair of Tessera Therapeutics, chief innovation officer and board director of Indigo Agriculture, board director of Quotient and Mirai, and as CEO of multiple new stealth therapeutics and sustainability companies. Geoffrey has served as founding chief executive officer of several Flagship companies including: Tessera Therapeutics, where he led the development of its pioneering Gene Writing鈩� technology; Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology; and Indigo, where he led the development of the company鈥檚 plant microbiome platform and the discovery of the company鈥檚 first commercial products: Indigo Cotton, Indigo Wheat, Indigo Corn, and Indigo Soy, which are now used on millions of acres. Previously, Geoffrey was the chief technology officer of Seres Therapeutics, where he led the discovery of SER-109, the first microbiome therapeutic to report positive Phase 3 data, and built out the company鈥檚 discovery platform.